R&D
Functional Probiotics
Functional Probiotic Pipeline - Muscle Function & Strength
Pipeline
Function
Research
Preclinical
Human study
Commercialization
Sarcopenia is a musculoskeletal disorder characterized by the progressive loss of muscle mass, strength, and physical function. It can impair daily activities, increase the risk of falls, and is associated with higher mortality. Although sarcopenia is most prevalent in older adults, it can also occur in younger populations due to factors such as nutritional imbalance, chronic disease, and reduced physical activity.
Age-related sarcopenia, in particular, has emerged as a growing societal challenge, underscoring the importance of early intervention and preventive strategies to preserve muscle health.
ATG-F4 demonstrated anti-inflammatory effects in induced muscle atrophy models by suppressing key inflammatory markers, including TNF-α and IL-6, in both blood and muscle tissue.
ATG-F4 also enhanced muscle protein synthesis through upregulation of mTOR signaling while reducing the expression of muscle atrophy–related factors such as MuRF1.
ATG-F4 also enhanced muscle protein synthesis through upregulation of mTOR signaling while reducing the expression of muscle atrophy–related factors such as MuRF1.
Based on these findings, ATG-F4 showed potential to increase muscle mass, improve muscle strength, and enhance endurance, supporting its development as a functional ingredient for muscle health maintenance and sarcopenia prevention.